Indium (111In) satumomab pendetide

Indium (¹¹¹In) satumomab pendetide
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	TAG-72
Identifiers
CAS Number	144058-40-2
ATC code	V09IB02
ChemSpider	none
Synonyms	MAb B72.3-GYK-DTPA

^NY (what is this?) (verify)

Indium (¹¹¹In) satumomab pendetide (trade name OncoScint CR103) is a mouse monoclonal antibody which is used for cancer diagnosis.^[1] The antibody itself, satumomab, is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111.

References

↑ García-fernández; Luna-Pérez, P.; Hernández-Hernández, D. M.; Iwasaki-Otake, L.; Pichardo-Romero, P.; Rodríguez-Ramirez, S. (2002). "Usefulness of scintigraphy images with 111In-CYT-103 in the diagnosis of colonic and rectal recurrence". Gaceta medica de Mexico 138 (2): 139–144. PMID 12001423.

External links

Drugs.com Satumomab pendetide

Diagnostic radiopharmaceuticals (V09)

Central nervous system	^99mTc (Exametazime) ¹²³I (Ioflupane Iofetamine Iomazenil) ¹⁸F (Florbetapir, Flutemetamol)

Skeletal system	^99mTc (Medronic acid)

Renal	¹²³I (Sodium iodohippurate) ⁶⁴Cu (Cu-ETS2)

Hepatic/reticuloendothelial	⁷⁵Se (SeHCAT)

Respiratory system	¹³³Xe ^81mKr

Cardiovascular system	^99mTc (Sestamibi Tetrofosmin) ¹¹¹In (Imciromab) ⁸²Rb (Rubidium chloride)

Inflammation/infection	^99mTc (Exametazime Sulesomab Tilmanocept) ¹¹¹In ⁶⁷Ga

Tumor	^99mTc (Arcitumomab Votumumab Hynic-octreotide) ¹¹¹In (Capromab pendetide Satumomab pendetide) ¹²⁵I ( Minretumomab) ¹²³I/¹³¹I (Iobenguane) ¹⁸F (Fludeoxyglucose Sodium fluoride)

Adrenal cortex	¹²³I/¹²⁵I (Iodocholesterol)

Radionuclides (including tracers)	positron (PET): ¹⁸F ¹¹C ⁶⁴Cu ¹³N ¹⁵O ⁶⁸Ga gamma ray/photon (SPECT/scintigraphy): ^99mTc ¹²³I ¹²⁵I ¹³¹I ¹¹¹In ⁵⁷Co ¹⁵³Sm ¹³³Xe ⁵¹Cr ^81mKr ²⁰¹Tl ⁶⁷Ga ⁷⁵Se

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Cixutumumab Conatumumab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Patritumab Pritumumab Radretumab Rilotumumab Robatumumab Seribantumab Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab "-melu-" (melanoma) Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Derlotuximab biotin Dinutuximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Margetuximab Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Alemtuzumab Bevacizumab Bivatuzumab mertansine Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Elotuzumab^† Emibetuzumab Enoblituzumab Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Matuzumab^§ Milatuzumab Nimotuzumab Obinutuzumab Ocaratuzumab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Sibrotuzumab Simtuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Veltuzumab Vorsetuzumab mafodotin "-gozu-" (ovarian tumor) Sofituzumab vedotin

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab

Chimeric + humanized ("-tuxizu-")	Ontuxizumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.